Cisen Pharmaceutical Co Ltd (603367.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100002VG4

Price
13.08 CNY
Market cap
5.92 bn CNY
P/E (2025)
14.06
P/S (2025)
1.72
Dividend yield
2.87 %
Net margin
12.23 %
Return on equity (ROE)
6.80 %
Return on assets (ROA)
5.54 %

Cisen Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue3.98 bn CNY3.44 bn CNY
Gross profit2.17 bn CNY1.79 bn CNY
Operating income572.05 m CNY376.64 m CNY
EBIT466.89 m CNY497.53 m CNY
Net income508.91 m CNY421.25 m CNY
Diluted EPS – continuing operations1.12 CNY0.93 CNY

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Cisen Pharmaceutical Co Ltd

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and analgesic drugs, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs, and hormonal drugs. It also offers Chinese medicine preparations; complete and incomplete nutritional formula food; specific nutritionally complete formula foods; nutritious food; health food; raw materials; and packaging products. The company was formerly known as Shandong Lukang Cisen Pharmaceutical Co., Ltd. and changed its name to Cisen Pharmaceutical Co., Ltd. in 2011. Cisen Pharmaceutical Co., Ltd. was founded in 1970 and is headquartered in Jining, the People's Republic of China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.